Raajit Rampal, MD, PhD

Panelists discuss how the future treatment landscape for myeloproliferative neoplasms is evolving with many promising therapies in development, including calreticulin antibodies, selective JAK2 inhibitors, and novel agents targeting various pathways.

Panelists discuss how rusfertide, a hepcidin mimetic peptide, shows promise in polycythemia vera by reducing phlebotomy requirements and potentially improving symptoms by altering iron homeostasis.

Panelists discuss how interferon therapy (particularly ropeginterferon) can provide better hematologic control over time and potentially modify disease progression in polycythemia vera patients.

Panelists discuss how to approach a 67-year-old man with advanced polycythemia vera who is resistant to hydroxyurea, requiring frequent phlebotomies despite maximum tolerated dosing, and experiencing new symptoms like night sweats and fatigue.

Panelists discuss how to monitor patients on JAK inhibitors, including blood count checks every 1 to 2 weeks initially, baseline spleen imaging with follow-up at 3 to 6 months, and symptom burden assessment.

Panelists discuss how to select among the four available JAK inhibitors (Ruxolitinib, Fedratinib, Pacritinib, and Momelotinib) based on patient-specific factors such as anemia, thrombocytopenia, and symptom burden.

Panelists discuss how JAK inhibitor therapy can benefit patients with intermediate-1–risk myelofibrosis despite being studied primarily in higher-risk patients in the COMFORT and JUMP trials.

Panelists discuss how risk stratification, symptom burden, and splenomegaly guide treatment decisions for a 68-year-old woman with intermediate-risk myelofibrosis who isn’t interested in transplant.

Raajit K. Rampal, MD, PhD, discusses how the field of gene therapy and precision medicine is evolving in the context of myelofibrosis treatment.

Raajit K. Rampal, MD, PhD, discusses some of the promising emerging therapies for myelofibrosis that target different pathways at the Fifth Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies, hosted by Dr. Guenther Koehne and Miami Cancer Institute.

Raajit K. Rampal, MD, PhD, discusses the established role of JAK inhibition for the treatment of myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses the MANIFEST-2 trial, a phase 3 study comparing ruxolitinib vs pelabresib and ruxolitinib combined with placebo for the treatment of myelofibrosis.

Raajit K. Rampal, MD, PhD, discusses some of the key takeaways from the 2023 American Society of Hematology Annual Meeting and what he believes holds promise for the space in 2024.

Raajit K. Rampal, MD, PhD, discusses the evolution of treatments for patients with myelofibrosis, and notes what he is excited to see more of in the future.

Raajit Rampal, MD, PhD, discusses unmet needs for therapies to treat patients with myelofibrosis.

Raajit Rampal, MD, PhD, discusses the current treatment landscape for patients with myelofibrosis.

Raajit Rampal, MD, PhD, discusses his recommended approach to assessing and treating patients with myelofibrosis.

Raajit Rampal, MD, PhD, discusses the challenges and unmet needs of myelofibrosis treatments and highlights promising investigational therapies.

Dr Raajit Rampal provides a brief overview of the criteria used to define response to myelofibrosis treatment.

Dr Raajit Rampal discusses factors to consider when switching between therapies among patients with myelofibrosis.

Raajit Rampal, MD, PhD, reviews data from the PERSIST trials which support the use of pacritinib for myelofibrosis treatment.

An overview of the currently available treatment options in myelofibrosis.

An explanation of the clinical phenotypes of myelofibrosis.

Dr Raajit Rampal assesses whether frontline treatment with ruxolitinib was appropriate in the presented patient case with supporting data from the COMFORT-I and -II clinical trials.

Raajit Rampal, MD, PhD, reviews the case of a 67-year-old man with primary myelofibrosis and shares his initial impressions.